Introduction: Vitamin K antagonist therapy is safest and most effective with a high time within the therapeutic range (TTR). The TTR is difficult to calculate in the consultation room, therefore physicians need an easier-to-use tool to predict poor VKA control. We explored the prognostic value of subtherapeutic INRs on future TTR in two settings: MATERIALS AND METHODS: Retrospective cohort of 17,711 patients from a dedicated thrombosis service, using acenocoumarol (target range 2.0-3.0), with a "streak" defined as four consecutive INRs <2.0.
Results And Conclusions: Clinical review setting: The occurrence of any streak in the last 180 days or 1 year increased the odds of a TTR <45%: ORs 2.84 (95% CI 2.41-3.34) and 3.25 (95% CI 2.72-3.87), respectively. Day-to-day INR management setting: A current streak increases the odds of poor TTR over the next 90 days 3.58 (95% CI 2.64-4.87) fold. We conclude that a streak of four consecutive subtherapeutic INRs can aid physicians in flagging at-risk patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.thromres.2019.06.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Quality of warfarin management following transfer from an anticoagulation clinic to primary care.
Thromb Res
January 2025
Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. Electronic address:
Background: Advances in alternative oral anticoagulants has reduced use and clinician comfort with warfarin. Our specialty anticoagulation clinic (AC) operates at maximum capacity and must transfer patients to accept new referrals.
Objectives: To compare time within therapeutic range (TTR) during 6 months of AC care versus following transfer to primary care for a minimum of 6 months and to a maximum of 24 months.
Safety of enoxaparin in patients implanted with continuous flow left ventricular assist devices.
Artif Organs
November 2024
US Clinical Development, Medical and Regulatory Affairs, Novonordisk, Rochester, Minnesota, USA.
Background: The objective of this study is to determine the incidence of major bleeding events in patients implanted with continuous flow left ventricular assist devices (CF-LVADs) bridged with enoxaparin (LMWH) compared to intravenous unfractionated heparin (IV UFH) for a subtherapeutic INR on warfarin.
Methods: A single-center, retrospective, cohort study was conducted including patients with CF-LVADs implanted between January 1, 2012 and July 1, 2020 who received at least one inpatient dose or outpatient prescription for LMWH or IV UFH at least 60 days after CF-LVAD implantation. The primary endpoint was the incidence of major bleeding.
Advances in left ventricular assist device technologies have led to an improvement in pump hemocompatibility and outcomes. Because of concerns of thromboembolic complications in prior generations of left ventricular assist devices, bridging with parenteral anticoagulants was routinely. Management strategies of subtherapeutic INRs and their effects on the current generation of devices deserve review.
View Article and Find Full Text PDFThe effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists.
Thromb Res
August 2023
Department of Hematology, Erasmus MC, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Thrombosis Service Star-shl, Rotterdam, the Netherlands. Electronic address:
Article Synopsis
- - The study investigated how COVID-19 vaccination affects anticoagulation stability in adolescents and young adults (AYAs) who use vitamin K antagonists (VKAs) for blood thinning, revealing a 20.8% decrease in INRs within the therapeutic range after the first vaccination.
- - Among the 101 AYAs included, there was a notable increase in supratherapeutic INRs (16.8%) after the first vaccination, while results after the second vaccination showed no significant changes compared to pre-vaccination levels.
- - Although the stability of anticoagulation was reduced post-vaccination, the study concluded that this change was likely not clinically significant, as complications from bleeding were less frequent and no severe issues
Medication adverse events in the ambulatory setting: A mixed-methods analysis.
Am J Health Syst Pharm
December 2022
Center for Excellence in Primary Care, Department of Family & Community Medicine, University of California San Francisco, San Francisco, CA.
Purpose: To characterize ambulatory care adverse drug events reported to the Collaborative Healthcare Patient Safety Organization (CHPSO), a network of 400 hospitals across the United States, and identify addressable contributing factors.
Methods: We abstracted deidentified ambulatory care CHPSO reports compiled from May 2012 to October 2018 that included medication-related adverse events to identify implicated medications and contributing factors. We dual-coded 20% of the sample.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!